We are thankful this year for the development contract signed this week with Amwise Diagnostics to develop RecurIndex® (the only Asian-specific breast cancer treatment selection panel on the market) using QuarkBio’s PanelChip® Analysis System. Together, we will enter the Chinese market, starting with a clinical trial on 3,000 samples from Guangzhou’s Sun Yat-Sen’s Memorial Hospital.
If you’re also interested in developing an expression-based biomarker panel, contact us today to discuss your project needs.
